2 results
Approved WMORecruiting
•To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between sacituzumab govitecan (SG) versus treatment of physician*s choice (TPC)Secondary Objectives:•To compare overall survival (OS) between the 2…
Approved WMORecruiting
To compare the overall survival (OS) of sacituzumab govitecan (SG) versus docetaxel.